Fig 1.
Flow chart of study participants throughout the trial.
Of the 250 patients who were enrolled, 209 patients (azelnidipine group: 103 patients, trichlormethiazide group: 106 patients) completed the trial. Seventeen patients in the azelnidipine group and fourteen patients in the trichlormethiazide group were excluded because they were lost-to-follow-up or because of missing data.
Table 1.
Baseline characteristics of the subjects.
Table 2.
Time courses for clinical parameters in the azelnidipine group and the trichlormethiazide group.
Table 3.
Changes in clinical parameters at 48 weeks relative to baseline values.
Table 4.
Changes in clinical parameters at 48 weeks relative to baseline values in per-protocol analyses.